Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223949170> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2223949170 endingPage "266" @default.
- W2223949170 startingPage "266" @default.
- W2223949170 abstract "266 Background: Addition of erlotinib (E) to gemcitabine (G) results in improved OS for patients (pts) with advanced pancreatic cancer. Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF. Sorafenib (S), a multitargeted tyrosine kinase inhibitor, including VEGR 1-3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize, resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression, and improved outcome. Methods: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, PS 0-1, and adequate organ function were eligible and received G 1,000 mg/m 2 over 30 min qw x 3 every 4w. E 150 mg PO daily and S 400 mg PO bid were given continuously. CT scans were performed every 2 cycles (8w). Primary endpoint included PFS at 4 mos and secondary endpoints included safety and tolerability of the novel combination, RR, and OS. Results: 45 pts enrolled, 44 evaluable for toxicity(1 not treated), and 30 evaluable for response. Median age was 64 (45-84), 32 males (71%), 43 (96%) had metastatic disease, PS was 0 in 26 (58%). Median number of cycles was 2 (0-10). Grade (gr) 3 toxicity included: thrombocytopenia 5; diarrhea 4; vomiting 4; HFS, hyperbilirubinemia, hyperglycemia and SOB each 3 pts; 1 bowel perforation and 1 epistaxis. Gr 4 toxicity included 1 each: bowel perforation, GI bleed, transaminitis, hyperglycemia and sepsis with hypotension. 2 patients only required dose reduction of S for HFS. There were 2 PR (7%), 13 SD (43%), overall RR of 7% and DCR of 50%. Median TTP 111 days (95% CI = 53-175) and median OS 195 days (144-290). PFS at 16 weeks was 49%, just reaching statistical significance. Conclusions: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to G alone, except for very manageable cutaneous reactions. While the primary endpoint met our pre-determined criteria (compared with NCIC PA.3), this study does not suggest a major benefit for addition of S to G-E when compared to published data. Supported in part by grants from Bayer Healthcare Pharmaceuticals/Onyx and OSI. No significant financial relationships to disclose." @default.
- W2223949170 created "2016-06-24" @default.
- W2223949170 creator A5015750678 @default.
- W2223949170 creator A5017215021 @default.
- W2223949170 creator A5030301998 @default.
- W2223949170 creator A5030753298 @default.
- W2223949170 creator A5033532812 @default.
- W2223949170 creator A5048973199 @default.
- W2223949170 creator A5074248405 @default.
- W2223949170 creator A5082566518 @default.
- W2223949170 date "2011-02-01" @default.
- W2223949170 modified "2023-09-24" @default.
- W2223949170 title "Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer." @default.
- W2223949170 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.266" @default.
- W2223949170 hasPublicationYear "2011" @default.
- W2223949170 type Work @default.
- W2223949170 sameAs 2223949170 @default.
- W2223949170 citedByCount "4" @default.
- W2223949170 countsByYear W22239491702013 @default.
- W2223949170 countsByYear W22239491702019 @default.
- W2223949170 countsByYear W22239491702022 @default.
- W2223949170 crossrefType "journal-article" @default.
- W2223949170 hasAuthorship W2223949170A5015750678 @default.
- W2223949170 hasAuthorship W2223949170A5017215021 @default.
- W2223949170 hasAuthorship W2223949170A5030301998 @default.
- W2223949170 hasAuthorship W2223949170A5030753298 @default.
- W2223949170 hasAuthorship W2223949170A5033532812 @default.
- W2223949170 hasAuthorship W2223949170A5048973199 @default.
- W2223949170 hasAuthorship W2223949170A5074248405 @default.
- W2223949170 hasAuthorship W2223949170A5082566518 @default.
- W2223949170 hasConcept C121608353 @default.
- W2223949170 hasConcept C126322002 @default.
- W2223949170 hasConcept C143998085 @default.
- W2223949170 hasConcept C197934379 @default.
- W2223949170 hasConcept C203092338 @default.
- W2223949170 hasConcept C2777909004 @default.
- W2223949170 hasConcept C2778019345 @default.
- W2223949170 hasConcept C2778087573 @default.
- W2223949170 hasConcept C2778375690 @default.
- W2223949170 hasConcept C2778496288 @default.
- W2223949170 hasConcept C2778695046 @default.
- W2223949170 hasConcept C2779438470 @default.
- W2223949170 hasConcept C2780210213 @default.
- W2223949170 hasConcept C2780258809 @default.
- W2223949170 hasConcept C29730261 @default.
- W2223949170 hasConcept C31760486 @default.
- W2223949170 hasConcept C526805850 @default.
- W2223949170 hasConcept C535046627 @default.
- W2223949170 hasConcept C71924100 @default.
- W2223949170 hasConcept C90924648 @default.
- W2223949170 hasConceptScore W2223949170C121608353 @default.
- W2223949170 hasConceptScore W2223949170C126322002 @default.
- W2223949170 hasConceptScore W2223949170C143998085 @default.
- W2223949170 hasConceptScore W2223949170C197934379 @default.
- W2223949170 hasConceptScore W2223949170C203092338 @default.
- W2223949170 hasConceptScore W2223949170C2777909004 @default.
- W2223949170 hasConceptScore W2223949170C2778019345 @default.
- W2223949170 hasConceptScore W2223949170C2778087573 @default.
- W2223949170 hasConceptScore W2223949170C2778375690 @default.
- W2223949170 hasConceptScore W2223949170C2778496288 @default.
- W2223949170 hasConceptScore W2223949170C2778695046 @default.
- W2223949170 hasConceptScore W2223949170C2779438470 @default.
- W2223949170 hasConceptScore W2223949170C2780210213 @default.
- W2223949170 hasConceptScore W2223949170C2780258809 @default.
- W2223949170 hasConceptScore W2223949170C29730261 @default.
- W2223949170 hasConceptScore W2223949170C31760486 @default.
- W2223949170 hasConceptScore W2223949170C526805850 @default.
- W2223949170 hasConceptScore W2223949170C535046627 @default.
- W2223949170 hasConceptScore W2223949170C71924100 @default.
- W2223949170 hasConceptScore W2223949170C90924648 @default.
- W2223949170 hasIssue "4_suppl" @default.
- W2223949170 hasLocation W22239491701 @default.
- W2223949170 hasOpenAccess W2223949170 @default.
- W2223949170 hasPrimaryLocation W22239491701 @default.
- W2223949170 hasRelatedWork W2002341729 @default.
- W2223949170 hasRelatedWork W2036821810 @default.
- W2223949170 hasRelatedWork W2057074797 @default.
- W2223949170 hasRelatedWork W2063123552 @default.
- W2223949170 hasRelatedWork W2081973101 @default.
- W2223949170 hasRelatedWork W2163866397 @default.
- W2223949170 hasRelatedWork W2184836338 @default.
- W2223949170 hasRelatedWork W2248474846 @default.
- W2223949170 hasRelatedWork W2597291017 @default.
- W2223949170 hasRelatedWork W2187801383 @default.
- W2223949170 hasVolume "29" @default.
- W2223949170 isParatext "false" @default.
- W2223949170 isRetracted "false" @default.
- W2223949170 magId "2223949170" @default.
- W2223949170 workType "article" @default.